Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Revelation Biosciences, Inc. (REVB : NSDQ)
 
 • Company Description   
Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra Acquisition Inc., is based in NEW YORK.

Number of Employees: 9

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.84 Daily Weekly Monthly
20 Day Moving Average: 249,734 shares
Shares Outstanding: 1.53 (millions)
Market Capitalization: $4.36 (millions)
Beta: -0.08
52 Week High: $93.60
52 Week Low: $2.11
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 19.13% 13.14%
12 Week -67.69% -71.86%
Year To Date -87.17% -88.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4660 LAJOLLA VILLAGE DRIVE SUITE 100
-
SAN DIEGO,CA 92122
USA
ph: 650-800-3717
fax: -
mike@plrinvest.com http://www.revbiosciences.com
 
 • General Corporate Information   
Officers
James Rolke - Chief Executive Officer and President
George Tidmarsh - Chairman
Chester S. Zygmont - Chief Financial Officer
Jess Roper - Director
Jennifer Carver - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 76135L705
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/08/25
Share - Related Items
Shares Outstanding: 1.53
Most Recent Split Date: 7.00 (0.33:1)
Beta: -0.08
Market Capitalization: $4.36 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-3.71 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-14.19 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.30
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 94.64%
vs. Previous Quarter: 57.63%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -299.46
12/31/24 - -203.77
ROA
06/30/25 - -
03/31/25 - -115.36
12/31/24 - -90.91
Current Ratio
06/30/25 - -
03/31/25 - 3.60
12/31/24 - 3.43
Quick Ratio
06/30/25 - -
03/31/25 - 3.60
12/31/24 - 3.43
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 9.55
12/31/24 - 27.05
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©